Is Diarrhea a Side Effect of Wegovy? Understanding the Connection

Last reviewed: July 7, 2026

Last updated: July 7, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Yes — diarrhea is a labeled adverse reaction of Wegovy, and a common one. The FDA prescribing information reports diarrhea in 30% of patients treated with the 2.4 mg injection compared with 16% on placebo in the weight-reduction trials. It is not a rare or idiosyncratic event, it is not a sign that something has gone wrong, and it is not unique to Wegovy — gastrointestinal effects are the defining tolerability issue for this entire drug class. What matters is understanding why it happens, when it tends to happen, and which version of it warrants a call to your prescriber.

What the Label Actually Reports

Diarrhea sits inside a cluster of gastrointestinal reactions that dominate the adverse reaction table. Against placebo, the label reports nausea in 44% versus 16%, diarrhea in 30% versus 16%, vomiting in 24% versus 6%, and constipation in 24% versus 11%. Two features of that table are worth reading carefully.

First, the placebo rate for diarrhea is 16% — meaning a meaningful share of these episodes would have happened anyway, in people making dietary changes and paying closer attention to their symptoms. Second, constipation appears at 24%, nearly as often as diarrhea. The same medication produces opposite bowel effects in different people, which is a strong hint that the mechanism is about motility and transit rather than about irritation.

Why a GLP-1 Medication Affects the Bowel

Wegovy delays gastric emptying — a fact the label states directly, and one of the mechanisms by which the medication reduces appetite and food intake. Slowing the rate at which the stomach empties changes the timing and volume of what reaches the small intestine, and the downstream gut has to accommodate that altered delivery pattern.

GLP-1 receptors are distributed through the gastrointestinal tract and the central nervous system, and receptor activation influences gut motility broadly rather than in one direction. That is the most plausible explanation for why the same drug produces diarrhea in roughly three in ten trial participants and constipation in roughly one in four. The gastrointestinal effects are not a side channel to the mechanism; they are adjacent to it.

When It Tends to Happen

Timing is the single most useful thing to know. The Wegovy label reports that these gastrointestinal reactions "were most frequently reported during dosage escalation" — the period when exposure is changing rather than the period when it is steady. That is also the reason the label is built around a stepwise escalation across multiple strengths in the first place.

The pivotal STEP 1 trial, published in The New England Journal of Medicine, described the same pattern in its 1,961 randomized adults: nausea and diarrhea were the most common adverse events with semaglutide, and they were "typically transient and mild-to-moderate in severity and subsided with time." Transient is not a promise for any individual, but it is what the aggregate data showed over 68 weeks.

How Often It Actually Ends Treatment

Frequency and severity are different questions, and the discontinuation figures separate them usefully. In the weight-reduction trials, 6.8% of patients on Wegovy 2.4 mg injection and 3.2% on placebo permanently discontinued because of adverse reactions. The most common reasons were nausea at 1.8% versus 0.2%, vomiting at 1.2% versus 0%, and diarrhea at 0.7% versus 0.1%.

Read that against the 30% incidence figure. Diarrhea affected roughly three in ten trial participants but ended treatment for roughly seven in a thousand. The overwhelming majority of episodes were manageable within continued treatment. STEP 1 reported a consistent picture, with 4.5% of the semaglutide group and 0.8% of the placebo group discontinuing owing to gastrointestinal events.

The Complication the Label Actually Warns About

The concern with diarrhea in this class is not the symptom itself but what sustained fluid loss can do. The Wegovy labeling directs clinicians to "monitor renal function in patients reporting adverse reactions to WEGOVY that could lead to volume depletion, especially during dosage initiation and escalation." Volume depletion from persistent gastrointestinal losses can precipitate acute kidney injury, and that risk is higher in people with existing kidney impairment or on medications that affect renal perfusion.

There is a second, quieter interaction. Because Wegovy delays gastric emptying, it has the potential to affect the absorption of concomitantly administered oral medications — and an episode of significant diarrhea layered on top of that can further disturb how other prescriptions behave. If you take oral medications where the level matters, that is a specific thing to raise with your prescriber and pharmacist rather than to manage yourself.

What Real-World Reporting Adds

Trial data describe monitored populations under protocol. A 2025 survey fielded to a nationally representative sample of 8,793 U.S. adults through the RAND American Life Panel, published in Rand Health Quarterly, asked people who had used GLP-1 agonists what they experienced. Among users, 34.3% reported diarrhea — 26.8% describing it as mild and 7.5% as serious. Nausea was reported by 52.0% and vomiting by 19.8%.

Those figures are self-reported, uncontrolled and span multiple products, so they are not comparable to a placebo-controlled adverse reaction table. What they usefully confirm is that the trial incidence is not an artifact of trial conditions: the proportion of people encountering diarrhea outside a study is broadly similar, and most of them describe it as mild.

When to Involve Your Prescriber

Nothing in this article is a management plan, and it should not be used as one. Persistent or severe diarrhea, symptoms that do not settle as the label's escalation pattern would suggest, signs of dehydration, or diarrhea occurring alongside severe abdominal pain are all reasons to contact the clinician who prescribed your medication rather than to wait it out or adjust anything on your own.

That routing is not caution for its own sake. Your prescriber can weigh whether the pattern fits the expected escalation-phase profile, whether your kidney function or other medications change the calculus, and whether anything else in your history explains the symptom better. Those judgments require your chart, and they are the reason the label points to renal monitoring rather than to a home remedy.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Is diarrhea a side effect of Wegovy?

Yes. The FDA prescribing information lists diarrhea as an adverse reaction occurring in 30% of patients treated with the 2.4 mg injection compared with 16% on placebo in the weight-reduction trials. It appears alongside nausea at 44% versus 16%, vomiting at 24% versus 6%, and constipation at 24% versus 11%. Gastrointestinal reactions are the most common adverse effects reported for this class of medication.

Why does Wegovy cause diarrhea in some people and constipation in others?

The label states that Wegovy delays gastric emptying, which changes the timing and volume of what reaches the intestine. GLP-1 receptor activation influences gut motility broadly rather than in a single direction, which is the most plausible explanation for why the label reports diarrhea in 30% of patients and constipation in 24% of the same trial population. The effect is on transit and motility rather than irritation.

When is diarrhea most likely to occur?

The Wegovy label reports that gastrointestinal adverse reactions were most frequently reported during dosage escalation — the period when exposure is changing rather than steady. The STEP 1 trial published in The New England Journal of Medicine described nausea and diarrhea as typically transient and mild-to-moderate in severity, subsiding with time. That is an aggregate pattern across 1,961 randomized adults, not a guarantee for any individual.

How often does diarrhea cause people to stop treatment?

Less often than the incidence figure suggests. In the weight-reduction trials, 6.8% of patients on the 2.4 mg injection and 3.2% on placebo permanently discontinued because of adverse reactions, with diarrhea specifically accounting for 0.7% versus 0.1%. So diarrhea affected roughly three in ten participants but ended treatment for roughly seven in a thousand. STEP 1 reported 4.5% versus 0.8% discontinuing owing to gastrointestinal events.

When should I contact my prescriber about it?

Persistent or severe diarrhea, symptoms that do not settle, signs of dehydration, or diarrhea alongside severe abdominal pain are all reasons to contact the clinician who prescribed your medication. The Wegovy label directs clinicians to monitor renal function in patients reporting reactions that could lead to volume depletion, especially during initiation and escalation, because sustained fluid loss can precipitate acute kidney injury.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.